Effectiveness of Levoamlodipine Maleate for Hypertension Compared with Amlodipine Besylate: a Pragmatic Comparative Effectiveness Study

作者：Ma, Wei; Sun, Ningling; Duan, Chongyang; Zhao, Lianyou; Hua, Qi; Sun, Yingxian; Dang, Aimin; Gao, Pingjin; Qu, Peng; Cui, Wei; Zhao, Luosha; Dong, Yugang; Cui, Lianqun; Qi, Xiaoyong; Jiang, Yinong; Xie, Jianhong; Li, Jun; Wu, Gang; Du, Xinping; Huo, Yong^*; Chen, Pingyan^*

来源：Cardiovascular Drugs and Therapy, 2021, 35(1): 41-50.

DOI：10.1007/s10557-020-07054-1

• Hypertension
• Comparative effectiveness research
• Cardiovascular events
• Amlodipine besylate
• Levoamlodipine maleate
• Pragmatic clinical trial

Purpose Antihypertensive treatment is the most important method to reduce the risk of cardiovascular events in hypertensive patients. However, there is scant evidence of the benefits of levoamlodipine maleate for antihypertensive treatment using a head-to-head comparison in the real-world. This study aims to examine the effectiveness of levoamlodipine maleate used to treat outpatients with primary hypertension compared with amlodipine besylate in a real-world setting. @@@ Methods This was a pragmatic comparative effectiveness study carried out at 110 centers across China in outpatients with primary hypertension treated with levoamlodipine maleate or amlodipine besylate, with 24 months of follow-up. The primary outcomes used for evaluating the effectiveness were composite major cardiovascular and cerebrovascular events (MACCE), adverse reactions, and cost-effectiveness. @@@ Results Among the included 10,031 patients, there were 482 MACCE, 223 (4.4%) in the levoamlodipine maleate group (n = 5018) and 259 (5.2%) in the amlodipine besylate group (n = 5013) (adjusted hazard ratio = 0.90, 95%CI: 0.75-1.08, P = 0.252). The levoamlodipine maleate group had lower overall incidences of any adverse reactions (6.0% vs. 8.4%, P < 0.001), lower extremity edema (1.1% vs. 3.0%, P < 0.001) and headache (0.7% vs. 1.1%, P = 0.045). There was a nearly 100% chance of the levoamlodipine maleate being cost-effective at a willingness to pay threshold of 150,000 Yuan per quality-adjusted life years (QALYs) gained, resulting in more QALYs (incremental QALYs: 0.00392) and cost savings (saving 2725 Yuan or 28.8% reduction in overall costs) per patient. @@@ Conclusion In conclusion, levoamlodipine maleate could reduce cost by 29% with a similar MACCE incidence rate and lower occurrence of adverse reactions (especially edema and headache) compared with amlodipine besylate.

• 单位
  中国医学科学院北京协和医院; 河北医科大学; 1; 上海交通大学; 中山大学; 中国医科大学; 北京大学; 武汉大学; 南方医科大学; y; 郑州大学